Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd is attractive because it already has PEMGARDA authorized by the U.S. FDA for pre-exposure COVID-19 prevention in certain immunocompromised patients, giving the company real clinical validation and a commercial starting point. Its next-generation candidate VYD2311 appears more scalable, with a P3 program expected to read out by YE2026, a projected 85% probability of success, and a target population far larger than PEMGARDA’s, while management believes its antibody approach has shown protection levels almost twice those of current mRNA vaccines. The LIBERTY head-to-head Phase 3 trial in ~210 healthy adults should strengthen labeling and promotion if positive, and the company’s COVID-19 and RSV opportunities together support a compelling long-term pipeline.

Invivyd is facing a weak fundamental setup because the latest CDC indicators still show COVID activity rising, with test positivity climbing from 3.8% to 4.8%, hospitalizations edging up from 0.6 to 0.7 per 100,000, and ED visits increasing from 0.3% to 0.4%. Although that supports demand for PEMGARDA, the broader opportunity looks limited by the fact that mortality remains unchanged at 0.1% as of 08/08/2026, suggesting transmission is not yet translating into a more severe market need. With hotspot states concentrated across TX, MS, CA, WA, NV, AZ, NM, AR, LA, AL, GA, SC, FL, NH, and HI, the company may see near-term utilization, but the business still depends on a narrow, episodic prevention niche rather than a durable, broad-based commercial franchise.